drugset / Trial / NCT00619931

A Multiple-Dose Study to Assess the Safety, Tolerability, and Steady State Pharmacokinetics of APD791 in Healthy Volunteers

NCT00619931

Phase 1 Completed 50 enrolled Arena Pharmaceuticals
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The APD791-002 study is designed primarily to evaluate the safety, tolerability, and pharmacokinetics of APD791 when administered for 7 days to healthy adult subjects.

Timeline

Start
2008-01
Primary completion
2008-06
Completion
2008-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Temanogrel Small molecule

Indications

No indication recorded.